A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

Dennis Bourdette, E. Edmonds, C. Smith, J. D. Bowen, C. R G Guttmann, Z. P. Nagy, J. Simon, Ruth Whitham, J. Lovera, Vijayshree Yadav, Michele Mass, L. Spencer, N. Culbertson, R. M. Bartholomew, G. Theofan, J. Milano, Halina Offner, Arthur Vandenbark

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: T cell receptor (TCR) peptide vaccination is a novel approach to treating multiple sclerosis (MS). The low immunogenicity of previous vaccines has hindered the development of TCR peptide vaccination for MS. Objective: To compare the immunogenicity of intramuscular injections of TCR BV5S2, BV6S5 and BV13S1 CDR2 peptides in incomplete Freund's adjuvant (IFA) with intradermal injections of the same peptides without IFA. Methods: MS subjects were randomized to receive TCR peptides/IFA, TCR peptides/saline or IFA alone. Subjects were on study for 24 weeks. Results: The TCR peptides/IFA vaccine induced vigorous T cell responses in 100% of subjects completing the 24-week study (9/9) compared with only 20% (2/10) of those receiving the TCR peptides/saline vaccine (P = 0.001). IFA alone induced a weak response in only one of five subjects. Aside from injection site reactions, there were no significant adverse events attributable to the treatment. Conclusions: The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.

Original languageEnglish (US)
Pages (from-to)552-561
Number of pages10
JournalMultiple Sclerosis
Volume11
Issue number5
DOIs
StatePublished - Oct 2005

Fingerprint

Subunit Vaccines
T-Cell Antigen Receptor
Multiple Sclerosis
Peptides
Vaccination
Vaccines
Intradermal Injections
Intramuscular Injections
incomplete Freund's adjuvant
T-Lymphocytes
Injections

Keywords

  • Immunoregulation
  • Multiple sclerosis
  • T cell receptor
  • Vaccine

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. / Bourdette, Dennis; Edmonds, E.; Smith, C.; Bowen, J. D.; Guttmann, C. R G; Nagy, Z. P.; Simon, J.; Whitham, Ruth; Lovera, J.; Yadav, Vijayshree; Mass, Michele; Spencer, L.; Culbertson, N.; Bartholomew, R. M.; Theofan, G.; Milano, J.; Offner, Halina; Vandenbark, Arthur.

In: Multiple Sclerosis, Vol. 11, No. 5, 10.2005, p. 552-561.

Research output: Contribution to journalArticle

Bourdette, D, Edmonds, E, Smith, C, Bowen, JD, Guttmann, CRG, Nagy, ZP, Simon, J, Whitham, R, Lovera, J, Yadav, V, Mass, M, Spencer, L, Culbertson, N, Bartholomew, RM, Theofan, G, Milano, J, Offner, H & Vandenbark, A 2005, 'A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis', Multiple Sclerosis, vol. 11, no. 5, pp. 552-561. https://doi.org/10.1191/1352458505ms1225oa
Bourdette, Dennis ; Edmonds, E. ; Smith, C. ; Bowen, J. D. ; Guttmann, C. R G ; Nagy, Z. P. ; Simon, J. ; Whitham, Ruth ; Lovera, J. ; Yadav, Vijayshree ; Mass, Michele ; Spencer, L. ; Culbertson, N. ; Bartholomew, R. M. ; Theofan, G. ; Milano, J. ; Offner, Halina ; Vandenbark, Arthur. / A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. In: Multiple Sclerosis. 2005 ; Vol. 11, No. 5. pp. 552-561.
@article{2fa7d3d1af3a40c592e3fbafb3febe38,
title = "A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis",
abstract = "Background: T cell receptor (TCR) peptide vaccination is a novel approach to treating multiple sclerosis (MS). The low immunogenicity of previous vaccines has hindered the development of TCR peptide vaccination for MS. Objective: To compare the immunogenicity of intramuscular injections of TCR BV5S2, BV6S5 and BV13S1 CDR2 peptides in incomplete Freund's adjuvant (IFA) with intradermal injections of the same peptides without IFA. Methods: MS subjects were randomized to receive TCR peptides/IFA, TCR peptides/saline or IFA alone. Subjects were on study for 24 weeks. Results: The TCR peptides/IFA vaccine induced vigorous T cell responses in 100{\%} of subjects completing the 24-week study (9/9) compared with only 20{\%} (2/10) of those receiving the TCR peptides/saline vaccine (P = 0.001). IFA alone induced a weak response in only one of five subjects. Aside from injection site reactions, there were no significant adverse events attributable to the treatment. Conclusions: The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.",
keywords = "Immunoregulation, Multiple sclerosis, T cell receptor, Vaccine",
author = "Dennis Bourdette and E. Edmonds and C. Smith and Bowen, {J. D.} and Guttmann, {C. R G} and Nagy, {Z. P.} and J. Simon and Ruth Whitham and J. Lovera and Vijayshree Yadav and Michele Mass and L. Spencer and N. Culbertson and Bartholomew, {R. M.} and G. Theofan and J. Milano and Halina Offner and Arthur Vandenbark",
year = "2005",
month = "10",
doi = "10.1191/1352458505ms1225oa",
language = "English (US)",
volume = "11",
pages = "552--561",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

AU - Bourdette, Dennis

AU - Edmonds, E.

AU - Smith, C.

AU - Bowen, J. D.

AU - Guttmann, C. R G

AU - Nagy, Z. P.

AU - Simon, J.

AU - Whitham, Ruth

AU - Lovera, J.

AU - Yadav, Vijayshree

AU - Mass, Michele

AU - Spencer, L.

AU - Culbertson, N.

AU - Bartholomew, R. M.

AU - Theofan, G.

AU - Milano, J.

AU - Offner, Halina

AU - Vandenbark, Arthur

PY - 2005/10

Y1 - 2005/10

N2 - Background: T cell receptor (TCR) peptide vaccination is a novel approach to treating multiple sclerosis (MS). The low immunogenicity of previous vaccines has hindered the development of TCR peptide vaccination for MS. Objective: To compare the immunogenicity of intramuscular injections of TCR BV5S2, BV6S5 and BV13S1 CDR2 peptides in incomplete Freund's adjuvant (IFA) with intradermal injections of the same peptides without IFA. Methods: MS subjects were randomized to receive TCR peptides/IFA, TCR peptides/saline or IFA alone. Subjects were on study for 24 weeks. Results: The TCR peptides/IFA vaccine induced vigorous T cell responses in 100% of subjects completing the 24-week study (9/9) compared with only 20% (2/10) of those receiving the TCR peptides/saline vaccine (P = 0.001). IFA alone induced a weak response in only one of five subjects. Aside from injection site reactions, there were no significant adverse events attributable to the treatment. Conclusions: The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.

AB - Background: T cell receptor (TCR) peptide vaccination is a novel approach to treating multiple sclerosis (MS). The low immunogenicity of previous vaccines has hindered the development of TCR peptide vaccination for MS. Objective: To compare the immunogenicity of intramuscular injections of TCR BV5S2, BV6S5 and BV13S1 CDR2 peptides in incomplete Freund's adjuvant (IFA) with intradermal injections of the same peptides without IFA. Methods: MS subjects were randomized to receive TCR peptides/IFA, TCR peptides/saline or IFA alone. Subjects were on study for 24 weeks. Results: The TCR peptides/IFA vaccine induced vigorous T cell responses in 100% of subjects completing the 24-week study (9/9) compared with only 20% (2/10) of those receiving the TCR peptides/saline vaccine (P = 0.001). IFA alone induced a weak response in only one of five subjects. Aside from injection site reactions, there were no significant adverse events attributable to the treatment. Conclusions: The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.

KW - Immunoregulation

KW - Multiple sclerosis

KW - T cell receptor

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=25844508410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844508410&partnerID=8YFLogxK

U2 - 10.1191/1352458505ms1225oa

DO - 10.1191/1352458505ms1225oa

M3 - Article

C2 - 16193893

AN - SCOPUS:25844508410

VL - 11

SP - 552

EP - 561

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 5

ER -